Skip to main content

Advertisement

Table 1 Demographics and clinical characteristics

From: Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases

  Treatment group No-treatment group
Age average (years) 50 44
 20–40 28 (23.9 %) 8 (40 %)
 41–50 30 (25.6 %) 4 (20 %)
 51–60 34 (29.1 %) 6 (30 %)
 61–80 25 (21.4 %) 2 (10 %)
Gender—number (%)
 Male 61 (52.1 %) 8 (40 %)
 Female 56 (47.9 %) 12 (60 %)
Race—number (%)
 African American 31 (26.5 %) 9 (45 %)
 Caucasian 66 (56.4 %) 7 (35 %)
 Hispanic 11 (9.4 %) 1 (5 %)
 Other 9 (7.7 %) 3 (15 %)
Years since diagnosis by physician 0.5–40 (range), 10.7 (mean), 5.0 (median) 0.5–17 (range), 7.3 (mean), 4.5 (median)
Years since initial episode 0.5–48 (range), 13.6 (mean), 9.0 (median) 0.5–17 (range), 11.4 (mean), 10.3 (median)
Diagnosed by physician—number (%) 91 (77.8 %) 17 (85 %)
 Lab test performed (out of those diagnosed by a physician)—number (%) 60 (65.9 %) 9 (52.9 %)
Symptoms of infection—number (%)
 Genital blisters/ulcers 102 (87.2 %) 18 (90 %)
 Anal blisters/ulcers 21 (17.9 %) 5 (25 %)
 Burning feeling while urinating 28 (23.9 %) 4 (20 %)
 Local pain 83 (70.9 %) 16 (80 %)
 Genital discharge 14 (12.0 %) 1 (5 %)
 General discomfort 64 (54.7 %) 11 (55 %)
 Light sensitivity 22 (18.8 %) 2 (10 %)
 Genital tingling sensation 80 (68.4 %) 13 (65 %)
 Genital itching sensation 80 (68.4 %) 13 (65 %)
 Flu-like symptoms 51 (43.6 %) 8 (40 %)
Duration of treatment (months)—number (%)
 2–3 22 (16.2 %) N/A
 4–6 24 (17.6 %) N/A
 8–12 31 (22.8 %) N/A
 16–24 25 (18.4 %) N/A
 25–48 14 (10.3 %) N/A
Dosage of treatment (capsules per day)—number (%)
 1 40 (31.2 %) N/A
 2 72 (56.3 %) N/A
 3 5 (3.9 %) N/A
 4 11 (8.6 %) N/A